Immunic AG Logo

Immunic AG

Developing oral therapies for autoimmune diseases like multiple sclerosis and celiac disease.

IMUX | NDAQ

Overview

Corporate Details

ISIN(s):
US4525EP1011
LEI:
549300R5T12FW5MEQB20
Country:
United States of America
Address:
C/O The Corporation Trust Company, 19801 Wilmington
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Immunic, Inc. is a clinical-stage biotechnology company developing a pipeline of selective, orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's development programs focus on creating convenient treatment options with high efficacy and favorable safety and tolerability profiles to address significant unmet patient needs. Its primary therapeutic areas of focus include multiple sclerosis and celiac disease.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Immunic AG and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-09 12:30
Regulatory News Service
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofl…
English 13.9 KB
2025-09-04 12:30
Regulatory News Service
Immunic to Participate in Investor and Scientific Conferences in September
English 15.6 KB
2025-08-07 12:30
Earnings Release
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corpor…
English 23.5 KB
2025-06-24 12:30
Regulatory News Service
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 …
English 15.2 KB
2025-06-05 12:30
Legal Proceedings Report
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Re…
English 18.3 KB
2025-06-02 12:30
Regulatory News Service
Immunic to Participate in Investor, Scientific and Industry Conferences in June
English 13.9 KB

Automate Your Workflow. Get a real-time feed of all Immunic AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Immunic AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Optipharm.CO.,LTD Logo
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea 153710
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea 476040
Oricon Inc. Logo
Provides entertainment industry data, music charts, web media, and marketing services.
Japan 4800
ORIENTBIO Inc. Logo
Provides animal models & technical services for preclinical R&D to pharma & research institutions.
South Korea 002630
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway PCIB

Talk to a Data Expert

Have a question? We'll get back to you promptly.